Protocol Ledger

NCT05832229 · Phase II · RECRUITING

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Interventional Phase II clinical trial protocol NCT05832229 sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-07 Enrollment: 260 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05832229
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)260 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05832229
Protocol FieldVerified Registry Value
NCT IdentifierNCT05832229
Consolidated Lead SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment260 participants (ESTIMATED)
Registered Start Date2023-12-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI